Could an antimalarial drug speed recovery from babesiosis?

NCT ID NCT06207370

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding the antimalarial drug tafenoquine to standard care helps hospitalized babesiosis patients recover faster. About 33 adults with confirmed Babesia infection will receive either tafenoquine or a placebo, plus standard antibiotics. Researchers will track how quickly symptoms like fever and fatigue resolve and whether the infection is cleared.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

tafenoquine (an antimalarial drug)

What this could lead to

If it works, this could provide a faster recovery and more effective treatment for hospitalized babesiosis patients.

What could go wrong

This is a small early-phase trial (33 people) testing a drug not yet approved for babesiosis. It may not show benefit or could have side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BABESIOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

babesiosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Tufts Medical Center

    RECRUITING

    Boston, Massachusetts, 02111, United States

    Contact Email: •••••@•••••

    Contact